557 related articles for article (PubMed ID: 32323067)
21. Biologics for chronic rhinosinusitis with nasal polyps.
Bachert C; Zhang N; Cavaliere C; Weiping W; Gevaert E; Krysko O
J Allergy Clin Immunol; 2020 Mar; 145(3):725-739. PubMed ID: 32145872
[TBL] [Abstract][Full Text] [Related]
22. [Treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) with monoclonal antibodies (biologics): S2k guideline of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), and the German College of General Practitioners and Family Physicians (DEGAM)].
Pfaar O; Beule AG; Laudien M; Stuck BA;
HNO; 2023 Apr; 71(4):256-263. PubMed ID: 36941387
[TBL] [Abstract][Full Text] [Related]
23. Pathogenesis-based application of biologics for chronic rhinosinusitis: Current and future perspectives.
Okano M; Kanai K; Oka A
Auris Nasus Larynx; 2024 Apr; 51(2):371-378. PubMed ID: 37743131
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of switching between biologics in chronic rhinosinusitis with nasal polyps or N-ERD.
Brkic FF; Liu DT; Klimbacher R; Campion NJ; Bartosik TJ; Vyskocil E; Stanek V; Tu A; Arnoldner T; Bangert C; Gangl K; Eckl-Dorna J; Schneider S
Rhinology; 2023 Aug; 61(4):320-327. PubMed ID: 37515811
[TBL] [Abstract][Full Text] [Related]
25. Chinese Expert Consensus on the Use of Biologics in Patients with Chronic Rhinosinusitis (2022, Zhuhai).
Hong HY; Chen TY; Yang QT; Sun YQ; Chen FH; Lou HF; Wang HT; Yu RL; An YF; Liu F; Wang TS; Lu MP; Qiu QH; Wang XD; Chen JJ; Meng CD; Xie ZH; Meng J; Zeng M; Xu CL; Wang Y; Yang YC; Zhang WT; Tang J; Yang YL; Xu R; Yu GD; Shi ZH; Wei X; Ye HP; Sun YN; Yu SQ; Zhang TH; Yong J; Hang W; Xu YT; Xu Y; Tan GL; Sun N; Yang G; Li YJ; Ye J; Zuo KJ; Zhang LQ; Wang XY; Yang AN; Xu YX; Liao W; Fan YP; Li HB
ORL J Otorhinolaryngol Relat Spec; 2023; 85(3):128-140. PubMed ID: 37019094
[TBL] [Abstract][Full Text] [Related]
26. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis.
Bachert C; Hellings PW; Mullol J; Hamilos DL; Gevaert P; Naclerio RM; Joish VN; Chao J; Mannent LP; Amin N; Abbe A; Taniou C; Fan C; Pirozzi G; Graham NMH; Mahajan P; Staudinger H; Khan A
Allergy; 2020 Jan; 75(1):148-157. PubMed ID: 31306495
[TBL] [Abstract][Full Text] [Related]
27. Biologics for the Treatment of Allergic Rhinitis, Chronic Rhinosinusitis, and Nasal Polyposis.
Eschenbacher W; Straesser M; Knoeddler A; Li RC; Borish L
Immunol Allergy Clin North Am; 2020 Nov; 40(4):539-547. PubMed ID: 33012318
[TBL] [Abstract][Full Text] [Related]
28. Adverse events of biological therapy in chronic rhinosinusitis with nasal polyps: A systematic review.
Aldajani A; Alroqi A; Alromaih S; Aloulah MO; Alsaleh S
Am J Otolaryngol; 2022; 43(6):103615. PubMed ID: 36057193
[TBL] [Abstract][Full Text] [Related]
29. Study protocol: the biologics in severe chronic rhinosinusitis with nasal polyps survey.
Favier V; Daveau C; Carsuzaa F; Fieux M; Vandersteen C; Castillo L; Papon JF; de Gabory L; Saroul N; Verillaud B; Rumeau C; Jankowski R; Michel J; de Bonnecaze G; Lecanu JB; Coste A; Béquignon E; Malard O; Mortuaire G
BMJ Open; 2024 May; 14(5):e083112. PubMed ID: 38749694
[TBL] [Abstract][Full Text] [Related]
30. Biologics for chronic rhinosinusitis with nasal polyps (CRSwNP).
Scadding GK; Scadding GW
J Allergy Clin Immunol; 2022 Mar; 149(3):895-897. PubMed ID: 34752829
[No Abstract] [Full Text] [Related]
31. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
32. Chronic Rhinosinusitis With Nasal Polyps: Quality of Life in the Biologics Era.
Mullol J; Azar A; Buchheit KM; Hopkins C; Bernstein JA
J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1434-1453.e9. PubMed ID: 35306180
[TBL] [Abstract][Full Text] [Related]
33. Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps.
Bhattacharyya N; Villeneuve S; Joish VN; Amand C; Mannent L; Amin N; Rowe P; Maroni J; Eckert L; Yang T; Khan A
Laryngoscope; 2019 Sep; 129(9):1969-1975. PubMed ID: 30720213
[TBL] [Abstract][Full Text] [Related]
34. Improvement in Smell Using Monoclonal Antibodies Among Patients With Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review.
Barroso B; Valverde-Monge M; Betancor D; Gómez-López A; Villalobos-Vilda C; González-Cano B; Sastre J
J Investig Allergol Clin Immunol; 2023 Dec; 33(6):419-430. PubMed ID: 37669083
[TBL] [Abstract][Full Text] [Related]
35. A review of phase III clinical trials of US FDA-approved biologic therapies for chronic rhinosinusitis with nasal polyposis.
Lelegren MJ; Son SY; Han JK; Lam KK
Immunotherapy; 2022 Jun; 14(8):655-662. PubMed ID: 35510314
[TBL] [Abstract][Full Text] [Related]
36. Targetable pathogenic mechanisms in nasal polyposis.
Schneider AL; Schleimer RP; Tan BK
Int Forum Allergy Rhinol; 2021 Aug; 11(8):1220-1234. PubMed ID: 33660425
[TBL] [Abstract][Full Text] [Related]
37. Dupilumab for the treatment of chronic rhinosinusitis with nasal polyposis.
Fokkens W; Van Der Lans R; Reitsma S
Expert Opin Biol Ther; 2021 May; 21(5):575-585. PubMed ID: 33724109
[No Abstract] [Full Text] [Related]
38. [Does aspirin therapy after desensitization still have a role in treatment of chronic rhinosinusitis with nasal polyposis in the era of biologics?].
Klimek F; Förster-Ruhrmann U; Hagemann J; Cuevas M; Gröger M; Klimek L
HNO; 2024 Jul; 72(7):484-493. PubMed ID: 38409556
[TBL] [Abstract][Full Text] [Related]
39. Which Is the Best Biologic for Nasal Polyps: Dupilumab, Omalizumab, or Mepolizumab? A Network Meta-Analysis.
Wu Q; Zhang Y; Kong W; Wang X; Yuan L; Zheng R; Qiu H; Huang X; Yang Q
Int Arch Allergy Immunol; 2022; 183(3):279-288. PubMed ID: 34607329
[TBL] [Abstract][Full Text] [Related]
40. Type 2 Biomarkers for the Indication and Response to Biologics in CRSwNP.
Guo CL; Liu FF; Wang DY; Liu Z
Curr Allergy Asthma Rep; 2023 Dec; 23(12):703-713. PubMed ID: 37987873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
